NTLA (Intellia Therapeutics) Research & Development: $361.17 Mil (TTM As of Mar. 2026)


NTLA Intellia Therapeutics Inc NTLA
70 GF Score
Price $15.50
GF Value $20.67
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Intellia Therapeutics Research & Development?

Intellia Therapeutics NTLA +1.64% 70 Research & Development is $361.17 Mil as of Mar. 2026. GuruFocus rates NTLA with a GF Score™ of 70/100 and a GF Value™ of $20.67 (Modestly Undervalued). The stock has 3 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Intellia Therapeutics's Research & Development for the three months ended in Mar. 2026 was $80.74 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was $361.17 Mil.

Intellia Therapeutics  (NAS:NTLA) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Intellia Therapeutics Research & Development Related Terms

Intellia Therapeutics Research & Development Historical Data

* Premium members only.

The historical data trend for Intellia Therapeutics's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Intellia Therapeutics Research & Development Chart

Intellia Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 229.81 419.98 435.07 466.31 388.86

Intellia Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 108.43 97.04 94.75 88.65 80.74
NTLA
70GF Score
Intellia Therapeutics Inc NTLA
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Intellia Therapeutics Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $361.17 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $361.17 Mil mean?
Intellia Therapeutics (NTLA) has a Research & Development of $361.17 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Intellia Therapeutics and its competitors.
Is Intellia Therapeutics' Research & Development too high?
Intellia Therapeutics' current Research & Development is $361.17 Mil. Overall, Intellia Therapeutics has a GF Score™ of 70/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Intellia Therapeutics' Research & Development compare to AUPH and OCUL?
Intellia Therapeutics' Research & Development of $361.17 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Intellia Therapeutics and its competitors. Intellia Therapeutics's current Research & Development is $361.17 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Intellia Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Intellia Therapeutics (NTLA) is currently considered Modestly Undervalued. The stock's GF Value™ is $20.67, compared to a current price of $15.50 — trading 25% below its estimated fair value. The current Research & Development is $361.17 Mil. Intellia Therapeutics' overall GF Score™ is 70/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Intellia Therapeutics (NTLA), the current Research & Development is $361.17 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Intellia Therapeutics (NTLA) Overvalued in 2026?

Based on GuruFocus' analysis, Intellia Therapeutics stock appears to be undervalued. The current stock price of $15.50 is trading 25% below its estimated GF Value™ of $20.67. GuruFocus considers Intellia Therapeutics to be Modestly Undervalued.

Key valuation signals for NTLA:

  • Research & Development: $361.17 Mil
  • GF Value™: $20.67 vs. price of $15.50 (25% below fair value)
  • GF Score™: 70/100 with 3 warning signs

No single metric tells the full story. See the NTLA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Intellia Therapeutics Business Description

Other Exchanges 0JBU:UK38I:Germany
Address 40 Erie Street, Suite 130, Cambridge, MA, USA, 02139
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
70GF Score

Get the complete analysis for NTLA

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$15.50
Price
$20.67
GF Value